BioXcel, a Branford, Conn.-based global provider of cloud-based big data platforms, has partnered with Cambridge, Mass.-based Pronutria Biosciences to identify diseases characterized by high unmet need for therapies and nutritional products that are amenable to Pronutria’s novel technology platform. Pronutria is a biotechnology company pioneering a new class of products to mediate amino acid biology.
Through the partnership, Pronutria will utilize BioXcel’s first-in-class Big Data Innovation Lab (BDI-Lab) to develop biologics that leverage its novel platform and amino acid-based approach. BDI-Lab is an integrated product discovery engine which applies big data algorithms, recursive mapping and network pharmacology to build associations and neural networks for deciphering novel treatment options for rare diseases with no current standard-of-care.
“We are pleased to partner with Pronutria to utilize the disruptive capabilities of our Big Data Innovation Lab and Orphan Disease Suite to work toward the discovery and development of novel products targeting areas of high unmet need. Our lab capitalizes on multiple proprietary innovations and algorithms designed to trigger underlying metadata and analyses of over 9,000 rare and ultra-rare diseases to identify novel product opportunities with transformative and life-saving potential,” said BioXcel CEO and Chairman Vimal Mehta, Ph.D.